Search results for "Anti-Arrhythmia Agents"

showing 10 items of 34 documents

Amiodarone pulmonary toxicity

2004

The amount of literature on amiodarone pulmonary toxicity (APT) peaked in 1983-1984 with several hundred cases reported cumulatively, and declined thereafter. Since the mid-1990s, publications have increased, which suggests that APT remains a current problem in clinical practice. Amiodarone remains difficult to diagnose noninvasively, and although the outcome is good in the majority of patients, not all cases of APT can be controlled satisfactorily.

Pulmonary and Respiratory Medicinemedicine.diagnostic_testbusiness.industryPulmonary toxicityIatrogenic DiseaseAmiodaronePneumoniaAmiodaroneBronchoalveolar LavageRespiratory Function TestsClinical PracticeBronchoalveolar lavageAnesthesiaIatrogenic diseaseHumansPleuraMedicinebusinessAnti-Arrhythmia AgentsLungmedicine.drugClinics in Chest Medicine
researchProduct

Biowaiver monographs for immediate release solid oral dosage forms: quinidine sulfate.

2009

Literature data are reviewed relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of new multisource and reformulated immediate release (IR) solid oral dosage forms containing quinidine sulfate. Quinidine sulfate's solubility and permeability, its therapeutic use and index, pharmacokinetics, excipient interactions and reported BE/bioavailability (BA) problems were taken into consideration. The available data are not fully conclusive, but do suggest that quinidine sulfate is highly soluble and moderately to highly permeable and would likely be assigned to BCS Class I (or at worst BCS III). In view of the inconclusiveness of the data and, more imp…

QuinidineDosage FormsChemistryBiopharmaceuticsPharmaceutical ScienceExcipientAdministration OralBiological AvailabilityPharmacologyBioequivalenceQuinidineDosage formPermeabilityBioavailabilityExcipientsAntimalarialsPharmacokineticsQuinidine SulfateSolubilityTherapeutic EquivalencymedicineHumansAnti-Arrhythmia AgentsDrug Approvalmedicine.drugJournal of pharmaceutical sciences
researchProduct

Metabolism of propafenone and verapamil by cryopreserved human, rat, mouse and dog hepatocytes: comparison with metabolism in vivo

2003

In the present study we examined the metabolism of [(14)C]propafenone (P) and [(14)C]verapamil (V) using cryopreserved human, dog (Beagle), rat (Sprague-Dawley) and mouse (NMRI) hepatocytes. The percentage ratios of the metabolites were identified after extraction by HPLC with UV and radioactivity detection. Phase-II metabolites were cleaved using beta-glucuronidase. Metabolism of the drugs by cryopreserved hepatocytes was compared with that in the respective species in vivo. All phase-I and -II metabolites known from in vivo experiments: 5-hydroxy-P (5-OH-P); 4'-hydroxy-P (4'-OH-P); N-despropyl-P (NdesP) and the respective glucuronides, were identified after incubation with cryopreserved h…

Time FactorsPropafenoneIn Vitro TechniquesPharmacologyCryopreservationRats Sprague-DawleyHydroxylationMicechemistry.chemical_compoundDogsGlucuronidesPropafenoneSpecies SpecificityIn vivomedicineAnimalsHumansIncubationAgedCryopreservationPharmacologyChemistryGeneral MedicineMetabolismMiddle AgedIn vitroRatsVerapamilBiochemistryHepatocytesVerapamilAnti-Arrhythmia Agentsmedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Vomilenine Reductase — a novel Enzyme catalyzing a crucial Step in the Biosynthesis of the Therapeutically applied Antiarrhythmic Alkaloid Ajmaline

2002

Delineation of the biochemical pathway leading to the antiarrhythmic Rauvolfia alkaloid ajmaline has been an important target in biosynthetic research for many years. The biosynthetic sequence starting with tryptamine and the monoterpene secologanin consists of about 10 different steps. Most of the participating enzymes have been detected and characterized previously, except those catalyzing the reduction of the intermediate vomilenine. A novel NADPH-dependent enzyme that reduces the intermediate has been isolated from Rauvolfia serpentina cell suspension cultures. Vomilenine reductase (M(r )43 kDa, temp opt 30 degrees C, pH opt 5.7-6.2), saturates the indolenine double bond of vomilenine w…

TryptamineRauvolfiaStereochemistryClinical BiochemistryPharmaceutical ScienceReductaseBiochemistryCatalysisRauwolfiaIndole Alkaloidschemistry.chemical_compoundRauvolfia serpentinaDrug DiscoverymedicineSecologanin Tryptamine AlkaloidsMolecular BiologyCells CulturedAjmalineChromatographyMolecular StructurebiologyOrganic ChemistryTemperatureHydrogen-Ion Concentrationbiology.organism_classificationSecologanin Tryptamine AlkaloidsAjmalinechemistryBiochemistryVomilenineMolecular MedicineSecologaninOxidoreductasesAnti-Arrhythmia AgentsNADPmedicine.drugBioorganic & Medicinal Chemistry
researchProduct

Polymorphism and solvates of flecainide base

2013

Flecainide base is pharmaceutically active substance used for production of flecainide acetate which is known in market as Tambacor, Almarytm, Apocard, Ecrinal or Flecaine. It is determined that flecainide base forms four polymorphic forms abbreviated as Ib, IIb, IIIb and IVb. Flecainide base form Ib is thermodynamically stable form at laboratory temperature while form IIIb is stable at higher temperatures. Flecainide form Ib absorbs water in its structure between layers and forms non-stoichiometric hydrate. Flecainide base binds with organic solvents and form monosolvates. Flecainide base form Ib crystallizes in orthorhombic crystals with lattice parameters a = 27.88 Å, b = 13.78 Å, c = 9.…

Voltage-Gated Sodium Channel BlockersFlecainideChemistryWaterPharmaceutical ScienceGeneral MedicineFlecainide Acetatelaw.inventionCrystallographyX-Ray DiffractionPolymorphism (materials science)lawX-ray crystallographymedicineThermodynamicsMoleculeOrthorhombic crystal systemCrystallizationCrystallizationHydrateAnti-Arrhythmia AgentsFlecainidemedicine.drugPharmaceutical Development and Technology
researchProduct

Effect of chronic exercise and ATP-sensitive potassium channel blockade on the spectral characteristics evolution of ventricular fibrillation in acut…

2013

Purpose: It has been proposed that chronic exercise produces a KATP channel blockade in ischemic myocardium. We have also reported that channel blockade and training exert very similar effects on energy required to defibrillate. In fact it is postulated that one mechanism by which exercise exerts an antiarrhythmic effect, is by blocking KATP channel. We have analyzed the evolution of spectrum characteristics of ventricular fibrillation (VF), in normoxic conditions and after acute myocardial ischemia, in isolated hearts from trained rabbits, and in hearts submitted to KATP channel blockade. Our hypothesis is that the spectrum characteristics of VF evolve similarly in trained hearts and in he…

medicine.medical_specialtyATP-sensitive potassium channelbusiness.industryIschemiamedicine.diseaseBlockadeGlibenclamidemedicine.anatomical_structureVentricleCoronary occlusionAnesthesiaInternal medicineVentricular fibrillationCardiologymedicineCardiology and Cardiovascular MedicinebusinessAnti-Arrhythmia Agentsmedicine.drugEuropean Heart Journal
researchProduct

Dofetilide effects on the inhibition by trains of subthreshold conditioning stimuli.

2004

We investigated the electrophysiological actions of dofetilide upon the ventricular myocardium to determine whether the drug modifies the inhibitory effects of subthreshold stimuli trains upon ventricular refractoriness. In nine Langendorff perfused rabbit hearts, ventricular epicardial electrodes were used to determine the following parameters at baseline and during dofetilide perfusion (0.5 micromolar): effective (ERP) and functional (FRP) refractory periods, conduction velocity (CV), wavelength (WL), and ERP prolongation (inhibitory effect) induced by subthreshold stimuli trains (STr) at pulse frequencies of 100, 300, and 600 Hz. Dofetilide significantly prolongs ventricular refractorine…

medicine.medical_specialtyCardiac Complexes PrematureRefractory Period ElectrophysiologicalHeart VentriclesDofetilideStimulationInhibitory postsynaptic potentialNerve conduction velocityElectrocardiographyHeart Conduction SystemInternal medicinePhenethylaminesmedicinePotassium Channel BlockersAnimalsSulfonamidesDose-Response Relationship DrugSubthreshold conductionPulse (signal processing)business.industryCardiac Pacing ArtificialGeneral MedicineElectric StimulationElectrophysiologyAnesthesiaModels AnimalCardiologyRabbitsCardiology and Cardiovascular MedicinebusinessPerfusionAnti-Arrhythmia Agentsmedicine.drugPacing and clinical electrophysiology : PACE
researchProduct

[Effect of flecainide on longitudinal and transverse conduction velocities in ventricular myocardium. An experimental study].

2007

It is known that the effect of flecainide on longitudinal and transverse ventricular conduction velocities depends on the coupling interval. If this is so, whether the longitudinal or transverse direction is predominantly affected could depend on the magnitude of the coupling interval. In order to investigate this hypothesis, we studied the effect of flecainide, 1 micromol/L, on conduction velocities in excised heart preparations from 11 rabbits using a basal cycle length of 250 ms and inserting two extrastimuli at a decreasing coupling interval. Flecainide significantly reduced both conduction velocities. However, the effect increased as the coupling interval decreased for only the longitu…

medicine.medical_specialtyFlecainidebusiness.industryHeartGeneral MedicineThermal conductionNerve conduction velocityVentricular myocardiumCoupling (electronics)Transverse planeHeart Conduction SystemInternal medicinemedicineCardiologyAnimalsVentricular FunctionRabbitsbusinessCycle lengthFlecainideTransverse directionAnti-Arrhythmia Agentsmedicine.drugRevista espanola de cardiologia
researchProduct

The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS

2008

Atrial fibrillation (AF) is the most common rhythm disturbance in medical practice and represents a very expensive health problem. AF can be managed with the prevention of thromboembolism and either a rate control of rhythm strategy. As both strategies have important limitations, probably a preventative strategy in patients at risk of developing arrhythmia can be a more attractive option. The renin-angiotensin system (RAS) seems to be involved in the genesis of arrhythmia by the following two mechanisms: 1. the induction of atrial fibrosis and structural remodelling by mitogen-activated protein kinase (MAPK) expression and reduction of collagenase activity; 2. the induction of electrical re…

medicine.medical_specialtyHeart diseaseGenotypeElectric CountershockAngiotensin-Converting Enzyme InhibitorsReview ArticleRenin-Angiotensin Systemrenin-angiotensin system atrial fibrillation ACE-I ARBDiabetes mellitusInternal medicineRenin–angiotensin systemAtrial FibrillationmedicineHumansPharmacology (medical)PharmacologyMitogen-Activated Protein Kinase KinasesEvidence-Based Medicinebiologybusiness.industryAngiotensin IIfungifood and beveragesAtrial fibrillationAngiotensin-converting enzymemedicine.diseaseAngiotensin IIEndocrinologyHeart failureACE inhibitorCardiologybiology.proteinbusinessAnti-Arrhythmia Agentsmedicine.drug
researchProduct

Pharmacological Therapy in Children with Atrial Fibrillation and Atrial Flutter

2008

Heart rhythm disorders in children are not different, on electrocardiographic trace, from heart rhythm disorders in adults with the exception of incidence which is different according to the age. Paticularly, atrial flutter (FlA) and fibrillation (FA) are very uncommon arrhythmias in the general pediatric population. Generally atrial fibrillation and atrial flutter, in our experience, is a temporary heart rhythm disturbance connected to specifical and resovable reasons with the exception of Fontains surgical correction of congenital heart diseases or cardiopathies with dilatation of both atria. Presenting symptoms, symptom history (e.g., frequency, duration, and severity), risk assessment, …

medicine.medical_specialtyHeart diseasemedicine.medical_treatmentAdrenergic beta-AntagonistsElectric CountershockPHARMACOLOGICAL THERAPY IN CHILDREN WITH ATRIAL FIBRILLATION AND ATRIAL FLUTTER.Catheter ablationElectrocardiographyPharmacotherapyInternal medicineAtrial FibrillationDrug DiscoverymedicineHumanscardiovascular diseasesChildUltrasonographyPharmacologyFibrillationmedicine.diagnostic_testbusiness.industryIncidence (epidemiology)Cardiac Pacing ArtificialAtrial fibrillationCalcium Channel Blockersmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareAtrial fibrillation atrial flutter pharmacological therapy childrenAtrial FlutterChronic DiseaseCatheter Ablationcardiovascular systemCardiologymedicine.symptombusinessAnti-Arrhythmia AgentsElectrocardiographyAtrial flutterCurrent Pharmaceutical Design
researchProduct